Compare ADMA Biologics Inc (ADMA) vs Paychex, Inc. (PAYX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Paychex, Inc. — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Paychex, Inc. trades at $106.56 (market cap $38.44B). The key difference: Paychex, Inc. is far larger — about 18× ADMA Biologics Inc's market cap, and Paychex, Inc. pays a 4.4% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | PAYX | |
|---|---|---|
Market Cap | $2.13B | $38.44B |
Sector | Health | Industrials |
52-Week High | $20.38 | $147.99 |
52-Week Low | $7.60 | $85.57 |
Enterprise Value | $2.20B | $41.92B |
Dividend Yield | — | 4.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Paychex (PAYX) trades at $108.12, up 1.66% today, showing strong momentum with three consecutive quarterly earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward movement, though RSI suggests mild overbought conditions. Fundamentally, the company maintains robust profitability with 27% net margins and 44.8% ROE, supported by steady revenue growth and strong cash flow generation.
The outlook remains positive with analyst consensus at $110 target and continued AI-driven growth initiatives. However, elevated valuation multiples and potential macroeconomic headwinds to small business hiring present risks. The stock offers a compelling combination of growth execution and shareholder returns through dividends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
